JP2022527334A5 - - Google Patents
Info
- Publication number
- JP2022527334A5 JP2022527334A5 JP2021558768A JP2021558768A JP2022527334A5 JP 2022527334 A5 JP2022527334 A5 JP 2022527334A5 JP 2021558768 A JP2021558768 A JP 2021558768A JP 2021558768 A JP2021558768 A JP 2021558768A JP 2022527334 A5 JP2022527334 A5 JP 2022527334A5
- Authority
- JP
- Japan
- Prior art keywords
- administered
- pharmaceutical composition
- antigen
- binding fragment
- oleculumb
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025166226A JP2026031542A (ja) | 2019-04-02 | 2025-10-02 | 腫瘍を処置するための抗ｃｄ７３、抗ｐｄ－ｌ１抗体及び化学療法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962828177P | 2019-04-02 | 2019-04-02 | |
| US62/828,177 | 2019-04-02 | ||
| PCT/IB2020/053110 WO2020202038A1 (en) | 2019-04-02 | 2020-04-01 | Anti-cd73, anti-pd-l1 antibodies and chemotherapy for treating tumors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025166226A Division JP2026031542A (ja) | 2019-04-02 | 2025-10-02 | 腫瘍を処置するための抗ｃｄ７３、抗ｐｄ－ｌ１抗体及び化学療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022527334A JP2022527334A (ja) | 2022-06-01 |
| JP2022527334A5 true JP2022527334A5 (https=) | 2023-11-08 |
Family
ID=72663659
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021558768A Pending JP2022527334A (ja) | 2019-04-02 | 2020-04-01 | 腫瘍を処置するための抗ｃｄ７３、抗ｐｄ－ｌ１抗体及び化学療法 |
| JP2025166226A Pending JP2026031542A (ja) | 2019-04-02 | 2025-10-02 | 腫瘍を処置するための抗ｃｄ７３、抗ｐｄ－ｌ１抗体及び化学療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025166226A Pending JP2026031542A (ja) | 2019-04-02 | 2025-10-02 | 腫瘍を処置するための抗ｃｄ７３、抗ｐｄ－ｌ１抗体及び化学療法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20200317803A1 (https=) |
| EP (1) | EP3947447A4 (https=) |
| JP (2) | JP2022527334A (https=) |
| KR (1) | KR20210148253A (https=) |
| CN (2) | CN113993890A (https=) |
| AU (2) | AU2020254100B9 (https=) |
| CA (1) | CA3134671A1 (https=) |
| EA (1) | EA202192587A1 (https=) |
| IL (1) | IL286504A (https=) |
| MA (1) | MA55558A (https=) |
| SG (1) | SG11202110694RA (https=) |
| TW (1) | TW202102545A (https=) |
| WO (1) | WO2020202038A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3194926A1 (en) * | 2020-09-23 | 2022-03-31 | Medimmune, Llc | Treatment methods using anti-cd73 and anti-pd-l1 antibodies and chemotherapy |
| JP2025512384A (ja) | 2022-04-13 | 2025-04-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｔｒｏｐ－２発現がんを治療するための併用療法 |
| WO2023227115A1 (en) * | 2022-05-26 | 2023-11-30 | I-Mab Biopharma Co., Ltd. | A method of treating solid tumor |
| EP4626552A1 (en) * | 2022-12-01 | 2025-10-08 | MedImmune Limited | Combination therapy for treatment of cancer comprising anti-pd-l1 and anti-cd73 antibodies |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| PL2504364T3 (pl) | 2009-11-24 | 2017-12-29 | Medimmune Limited | Ukierunkowane środki wiążące przeciwko B7-H1 |
| GB2537445A (en) * | 2014-11-10 | 2016-10-19 | Medimmune Ltd | Binding molecules specific for CD73 and uses thereof |
| EP3423494A1 (en) * | 2016-03-04 | 2019-01-09 | Bristol-Myers Squibb Company | Combination therapy with anti-cd73 antibodies |
| AU2017321609C1 (en) * | 2016-08-30 | 2023-11-09 | Dana-Farber Cancer Institute, Inc. | Drug delivery compositions and uses thereof |
| MY204117A (en) * | 2017-06-22 | 2024-08-08 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
-
2020
- 2020-04-01 EP EP20783214.8A patent/EP3947447A4/en not_active Withdrawn
- 2020-04-01 AU AU2020254100A patent/AU2020254100B9/en active Active
- 2020-04-01 JP JP2021558768A patent/JP2022527334A/ja active Pending
- 2020-04-01 WO PCT/IB2020/053110 patent/WO2020202038A1/en not_active Ceased
- 2020-04-01 CN CN202080039845.5A patent/CN113993890A/zh active Pending
- 2020-04-01 KR KR1020217035422A patent/KR20210148253A/ko active Pending
- 2020-04-01 EA EA202192587A patent/EA202192587A1/ru unknown
- 2020-04-01 MA MA055558A patent/MA55558A/fr unknown
- 2020-04-01 TW TW109111394A patent/TW202102545A/zh unknown
- 2020-04-01 US US16/837,477 patent/US20200317803A1/en not_active Abandoned
- 2020-04-01 CN CN202510064168.7A patent/CN119857140A/zh active Pending
- 2020-04-01 SG SG11202110694RA patent/SG11202110694RA/en unknown
- 2020-04-01 CA CA3134671A patent/CA3134671A1/en active Pending
-
2021
- 2021-09-19 IL IL286504A patent/IL286504A/en unknown
-
2025
- 2025-01-06 AU AU2025200063A patent/AU2025200063A1/en active Pending
- 2025-10-02 JP JP2025166226A patent/JP2026031542A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022527334A5 (https=) | ||
| JP2025020147A5 (https=) | ||
| CN100363004C (zh) | 喹唑啉衍生物zd6474组合吉西他滨在制备药物中的用途 | |
| Kitayama | Intraperitoneal chemotherapy against peritoneal carcinomatosis: current status and future perspective | |
| JP2023526451A5 (https=) | ||
| JP2020514311A5 (https=) | ||
| JP2014512356A5 (https=) | ||
| JP2012506448A5 (https=) | ||
| JP2021510725A5 (https=) | ||
| JP2016528162A5 (https=) | ||
| JP2012509889A5 (https=) | ||
| JP2003533485A5 (https=) | ||
| Sugawara et al. | Randomized phase II trial of uracil/tegafur and cisplatin versus vinorelbine and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage III non-small-cell lung cancer: NJLCG 0601 | |
| Takahashi et al. | Phase I trial evaluating the safety of preoperative gemcitabine/nab-paclitaxel with concurrent radiation therapy for borderline resectable pancreatic cancer | |
| JP2019038797A5 (https=) | ||
| JP2021511344A5 (https=) | ||
| Kunisaki et al. | Biweekly Docetaxel and S-1 combination chemotherapy as first-line treatment for elderly patients with advanced gastric cancer | |
| JP2007504259A5 (https=) | ||
| JP2021529777A5 (https=) | ||
| JP2020520385A5 (https=) | ||
| JP2024513247A5 (https=) | ||
| Hu et al. | Current status of CPT and its analogues in the treatment of malignancies | |
| JP2016522826A5 (https=) | ||
| Lee et al. | Weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma | |
| JP2025504278A5 (https=) |